Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban: Observations from the prospective EMIR Registry.
Esteve-Pastor MA, Rivera-Caravaca JM, Roldán V, Sanmartin Fernández M, Arribas F, Masjuan J, Barrios V, Cosin-Sales J, Freixa-Pamias R, Recalde E, Pérez-Cabeza AI, Manuel Vázquez Rodríguez J, Ràfols Priu C, Anguita Sánchez M, Lip GYH, Marin F.
Esteve-Pastor MA, et al. Among authors: lip gyh.
Eur Heart J Cardiovasc Pharmacother. 2022 Dec 15;9(1):38-46. doi: 10.1093/ehjcvp/pvac060.
Eur Heart J Cardiovasc Pharmacother. 2022.
PMID: 36318457